BioNTech SE

BNTX Nasdaq CIK: 0001776985

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
SEC Category Large accelerated filer
State of Incorporation Germany
Business Address AN DER GOLDGRUBE 12, MAINZ, 2M, 55131
Mailing Address AN DER GOLDGRUBE 12, MAINZ, 2M, 55131
Phone 0049613190840
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
6-K Foreign company current report April 2, 2026 View on SEC
20-F/A Foreign annual report amendment April 1, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
3 Initial insider ownership report March 25, 2026 View on SEC
6-K Foreign company current report March 24, 2026 View on SEC

Annual Reports

20-F March 10, 2026
  • Pioneered mRNA technology, driving the COVID-19 vaccine success and now diversifying into new therapeutic areas.
  • Aggressively investing in a diversified pipeline, with significant oncology advancements including a Phase 3 trial for BNT327/PM8002.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.